Cigna's Evernorth unit partners with Kaiser Permanente to gain access to doctors while travelling

Health insurer Cigna Corp's Evernorth unit would partner with Kaiser Permanente to help patients enrolled in some its rival's health plans gain access to doctors while traveling.

Alembic receives USFDA authorization to market generic drug for heart failure

Alembic Pharmaceuticals Limited today announced that it has received tentative approval from the US Food & Drug Administration for its Abbreviated New Drug Application (ANDA) for Ivabradine tablets, 5 mg and 7.5 mg.

Sanofi India assigns Rodolfo Hrosz as MD

Sanofi India Limited told that its Board of Directors has appointed Rodolfo Hrosz as the Company’s new Managing Director with effect from June 1, 2022, subject to regulatory approvals. He will transition from being Sanofi’s General Manager...

South Korea approves phase 3 clinical trial of breast cancer treatment 'Tucatinib'

Phase 3 clinical trials of new breast cancer treatment approved in the U.S. and Europe will be conducted in Korea.

Japan health ministry board approves Novavax's COVID-19 vaccine

A Japanese Health Ministry committee said on Monday it has approved Novavax Inc's COVID-19 vaccine, setting the stage for full approval of the country's fourth shot for the coronavirus.

Biocon Biologics to raise $1.2 billion offshore loan for Viatris deal

Biocon Biologics, a unit of Biocon, is raising $1.2 billion via an offshore loan with the pharmaceutical company likely appointing HSBC, MUFG and Standard Chartered Bank to underwrite the proposed five-year overseas loan, two sources familiar...

Ocugen acquired Covaxin to commercialise rights for all of North America

OcugenInc and Bharat Biotech declared that they have entered into an amendment to their co-development, supply and commercialisation agreement to expand Ocugen’s exclusive territory to include commercialisation of Covaxin in Mexico.

CCI confirm deal to acquire minority stake in BDR Pharmaceuticals

The Competition Commission of India approves acquisition of minority stake of BDR Pharmaceuticals International Private Limited (BDR/Target) by Multiples Private Equity Fund III, SRF Transnational Holdings Limited (SRF Transnational)...

QOL Medical selects Optum Frontier Therapies as pharmacy collaborates to support CSID patients on Sucraid oral solution

QOL Medical, LLC, a ground-breaking rare disease pharmaceutical firm, has selected Optum Frontier Therapies as its new pharmacy partner to support CSID patients nationwide being treated with Sucraid (sacrosidase) oral solution.

Omicron-specific Sinopharm & Sinovac Covid vaccine candidates cleared for clinical trail

COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong, the firms said on Saturday.

© 2025 India Pharma Outlook. All Rights Reserved.